248 related articles for article (PubMed ID: 34265363)
1. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.
Baghbani E; Noorolyai S; Shanehbandi D; Mokhtarzadeh A; Aghebati-Maleki L; Shahgoli VK; Brunetti O; Rahmani S; Shadbad MA; Baghbanzadeh A; Silvestris N; Baradaran B
Life Sci; 2021 Oct; 282():119826. PubMed ID: 34265363
[TBL] [Abstract][Full Text] [Related]
2. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
3. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
4. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
Kumar M; Lowery R; Kumar V
SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
[TBL] [Abstract][Full Text] [Related]
5. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
6. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
Allard B; Longhi MS; Robson SC; Stagg J
Immunol Rev; 2017 Mar; 276(1):121-144. PubMed ID: 28258700
[TBL] [Abstract][Full Text] [Related]
7. CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function.
Lee JJ; Jeong HJ; Kim MK; Wee WR; Lee WW; Kim SU; Sung C; Yang YH
Purinergic Signal; 2014; 10(2):357-65. PubMed ID: 24043462
[TBL] [Abstract][Full Text] [Related]
8. Targeting the adenosine pathway for cancer immunotherapy.
Hammami A; Allard D; Allard B; Stagg J
Semin Immunol; 2019 Apr; 42():101304. PubMed ID: 31604539
[TBL] [Abstract][Full Text] [Related]
9. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
[TBL] [Abstract][Full Text] [Related]
10. Targeting cancer-derived adenosine: new therapeutic approaches.
Young A; Mittal D; Stagg J; Smyth MJ
Cancer Discov; 2014 Aug; 4(8):879-88. PubMed ID: 25035124
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
[TBL] [Abstract][Full Text] [Related]
12. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.
Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
J Clin Invest; 2020 Mar; 130(3):1185-1198. PubMed ID: 31770109
[TBL] [Abstract][Full Text] [Related]
13. CD39 and CD73 in immunity and inflammation.
Antonioli L; Pacher P; Vizi ES; Haskó G
Trends Mol Med; 2013 Jun; 19(6):355-67. PubMed ID: 23601906
[TBL] [Abstract][Full Text] [Related]
14. CD73 and adenosine generation in the creation of regulatory microenvironments.
Regateiro FS; Cobbold SP; Waldmann H
Clin Exp Immunol; 2013 Jan; 171(1):1-7. PubMed ID: 23199317
[TBL] [Abstract][Full Text] [Related]
15. [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
Gros L; Paturel C; Perrot I; Bensussan A; Eliaou JF; Bastid J; Bonnefoy N
Med Sci (Paris); 2020 Feb; 36(2):112-115. PubMed ID: 32129745
[No Abstract] [Full Text] [Related]
16. ATP and adenosine: Role in the immunopathogenesis of rheumatoid arthritis.
da Silva JLG; Passos DF; Bernardes VM; Leal DBR
Immunol Lett; 2019 Oct; 214():55-64. PubMed ID: 31479688
[TBL] [Abstract][Full Text] [Related]
17. Purinergic Signaling in Pancreas-From Physiology to Therapeutic Strategies in Pancreatic Cancer.
Novak I; Yu H; Magni L; Deshar G
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233631
[TBL] [Abstract][Full Text] [Related]
18. Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors.
Ryzhov SV; Pickup MW; Chytil A; Gorska AE; Zhang Q; Owens P; Feoktistov I; Moses HL; Novitskiy SV
J Immunol; 2014 Sep; 193(6):3155-64. PubMed ID: 25127858
[TBL] [Abstract][Full Text] [Related]
19. CD39/CD73 and the imbalance of Th17 cells and regulatory T cells in allergic asthma.
Wang LL; Tang HP; Shi GC; Wan HY; Tang W; Hou XX; Pan LN; Shi BY; Tao LQ
Mol Med Rep; 2013 Nov; 8(5):1432-8. PubMed ID: 24065069
[TBL] [Abstract][Full Text] [Related]
20. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
